Shares of Equillium, Inc. (NASDAQ:EQ – Get Free Report) rose 1.1% during mid-day trading on Thursday . The stock traded as high as $1.85 and last traded at $1.81. Approximately 130,386 shares changed hands during mid-day trading, a decline of 59% from the average daily volume of 315,095 shares. The stock had previously closed at $1.79.
Analyst Upgrades and Downgrades
Separately, HC Wainwright lifted their price objective on Equillium from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd.
Read Our Latest Research Report on EQ
Equillium Stock Down 5.5 %
Equillium (NASDAQ:EQ – Get Free Report) last issued its quarterly earnings data on Monday, March 25th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.10. The firm had revenue of $9.21 million during the quarter, compared to the consensus estimate of $8.85 million. Equillium had a negative return on equity of 51.82% and a negative net margin of 36.96%. Sell-side analysts anticipate that Equillium, Inc. will post -0.08 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Equillium
An institutional investor recently bought a new position in Equillium stock. Decheng Capital LLC acquired a new stake in Equillium, Inc. (NASDAQ:EQ – Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 4,447,308 shares of the company’s stock, valued at approximately $3,215,000. Equillium accounts for 0.9% of Decheng Capital LLC’s holdings, making the stock its 18th biggest holding. Decheng Capital LLC owned 12.66% of Equillium as of its most recent filing with the Securities and Exchange Commission. 27.05% of the stock is owned by institutional investors and hedge funds.
Equillium Company Profile
Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.
Featured Articles
- Five stocks we like better than Equillium
- 3 Warren Buffett Stocks to Buy Now
- MarketBeat Week in Review – 4/22 – 4/26
- There Are Different Types of Stock To Invest In
- 3 Stocks Leading the U.S. Agriculture Comeback
- Which Wall Street Analysts are the Most Accurate?
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.